No Data
No Data
Scotiabank Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $76
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $73 to $94
9 Analysts Have This To Say About Legend Biotech
Legend Biotech (LEGN) Gets a Buy From Scotiabank
Legend Biotech Price Target Maintained With a $73.00/Share by HC Wainwright & Co.
Genscript Bio announced that the third-quarter net trade sales of CARVYKTI was approximately 0.286 billion US dollars.
Genscript Bio (01548) announced that Legend Biotech Co., Ltd. (Legend Biotech, a non-wholly-owned subsidiary of the company, whose shares are listed on the Nasdaq Global Select Market in the United States in the form of American depositary shares) submitted a 6-K form to the United States Securities and Exchange Commission (SEC) on October 15, 2024 (New York time, after the Hong Kong trading session on October 15, 2024).